Study on Relatlimab, Nivolumab, and Ipilimumab for Patients with Melanoma Brain Metastases

Inclusion Criteria

• Have melanoma that has spread to the brain, with at least one measurable brain tumor that hasn't been treated with local therapy.
• Be 18 years or older.
• Be in good overall health, with a performance status score of 0-1 for those without symptoms and 0-2 for those with symptoms.
• Have not received certain types of immunotherapy for advanced melanoma, unless it was more than 6 months ago.
• Have good organ function based on specific blood tests.
• Have recovered from any side effects of previous cancer treatments to a mild level.
• For those without symptoms: must not have needed steroids for brain symptoms recently. For those with symptoms: can be on a low dose of steroids or none at all.
• If HIV-positive, must be on effective treatment with an undetectable viral load.
• If previously infected with hepatitis B or C, must be treated and cured, or have an undetectable viral load if still on treatment.
• Provide a tumor sample for testing, if available.
• Any previous radiation or surgery to non-target brain tumors must have been done at least a week before starting the study.
• Women of childbearing potential must not be pregnant or breastfeeding and must use effective birth control during and after the study.
• Must understand the study and agree to participate by signing a consent form.

Exclusion Criteria

• Have another type of cancer within the last 3 years, except for certain treated cancers.
• Have active medical conditions that increase risk, like infections or major illnesses.
• Have an autoimmune disease needing treatment in the last 3 years.
• Have an implanted device that prevents MRI use.
• Have had severe side effects from similar treatments before.
• Have cancer spread to the brain's lining.
• Have had whole brain radiation therapy.
• Be pregnant or breastfeeding.
• Have significant heart disease or recent heart issues.
• Have high levels of certain heart-related proteins unless cleared by a cardiologist.
• Have used investigational drugs recently.
• Be on high doses of dexamethasone.